Skip to main content
. 2024 Aug 28;2:61. doi: 10.1038/s44276-024-00092-4

Fig. 1. Predicted survival estimates from the CheckMate 141 (nivolumab) trial according to the flexible parametric cure model (FPCM), Weibull non-mixture cure model (WNCM) and Kaplan–Meier (KM) curves.

Fig. 1

The FPCM is with knots at percentiles 0, 25, 50, 75, and 95, and 0.1 months after the time point of the last event.